Alkermes announced that its oral drug alixorexton significantly improved wakefulness and reduced daytime sleepiness in patients with narcolepsy type 1 during a Phase 2 clinical trial. While only the mid-dose group showed a statistically significant reduction in cataplexy attacks, the company attributes this to self-reporting methodology and plans to refine assessments in future studies. These results position Alkermes to advance the drug into Phase 3 and compete in a growing narcolepsy treatment market.